Published in PLoS One on November 11, 2011
TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer (2013) 0.89
Mucosal effects of tenofovir 1% gel. Elife (2015) 0.83
p15(PAF) is an Rb/E2F-regulated S-phase protein essential for DNA synthesis and cell cycle progression. PLoS One (2013) 0.82
NS5ATP9 contributes to inhibition of cell proliferation by hepatitis C virus (HCV) nonstructural protein 5A (NS5A) via MEK/extracellular signal regulated kinase (ERK) pathway. Int J Mol Sci (2013) 0.80
Paf15 expression correlates with rectal cancer prognosis, cell proliferation and radiation response. Oncotarget (2016) 0.77
Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary Tumors. Front Med (Lausanne) (2015) 0.76
Maintenance of the marginal-zone B cell compartment specifically requires the RNA-binding protein ZFP36L1. Nat Immunol (2017) 0.75
KIAA0101, a target gene of miR-429, enhances migration and chemoresistance of epithelial ovarian cancer cells. Cancer Cell Int (2016) 0.75
A network-pathway based module identification for predicting the prognosis of ovarian cancer patients. J Ovarian Res (2016) 0.75
NS5ATP9 suppresses activation of human hepatic stellate cells, possibly via inhibition of Smad3/phosphorylated-Smad3 expression. Inflammation (2015) 0.75
Adrenocortical carcinoma: clinical and laboratory observations. Cancer (2000) 2.64
Incidentally discovered adrenal masses. Endocr Rev (1995) 2.40
Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer (2008) 2.09
Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol (2003) 1.92
Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg (2006) 1.78
Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer (2008) 1.54
In search of adrenocortical stem and progenitor cells. Endocr Rev (2009) 1.51
Transplantation of adrenal cortical progenitor cells enriched by Nile red. J Surg Res (2009) 1.47
Different HATS of the ING1 gene family. Trends Cell Biol (2002) 1.45
p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues. Oncogene (2001) 1.41
ATF3 and p15PAF are novel gatekeepers of genomic integrity upon UV stress. Cell Death Differ (2009) 1.27
Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery (2005) 1.23
Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res (1996) 1.23
Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. Cancer Res (2007) 1.20
Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch Surg (2008) 1.18
Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol (2006) 1.15
Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J Clin Endocrinol Metab (1999) 1.14
The PCNA-associated factor KIAA0101/p15(PAF) binds the potential tumor suppressor product p33ING1b. Exp Cell Res (2005) 1.11
Cycling through metabolism. EMBO Mol Med (2010) 1.06
Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res (2007) 1.05
KIAA0101 interacts with BRCA1 and regulates centrosome number. Mol Cancer Res (2011) 1.04
Overexpressed in anaplastic thyroid carcinoma-1 (OEATC-1) as a novel gene responsible for anaplastic thyroid carcinoma. Cancer (2005) 1.01
Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients. Lung Cancer (2012) 1.00
High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood (2004) 1.00
Adrenocortical carcinoma. Our experience. Minerva Endocrinol (1995) 0.93
KIAA0101 (OEACT-1), an expressionally down-regulated and growth-inhibitory gene in human hepatocellular carcinoma. BMC Cancer (2006) 0.88
Genomic profiling of circulating plasma RNA for the analysis of cancer. Clin Chem (2007) 0.88
Gene expression profiling of adrenal cortical tumors by cDNA macroarray analysis. Results of a preliminary study. Biomed Pharmacother (2006) 0.84
[Adrenocortical tumors with oncocytic cells: benign or malignant?]. Ann Chir (2001) 0.84
Murine embryonic expression of the gene for the UV-responsive protein p15(PAF). Gene Expr Patterns (2006) 0.82
Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. N Engl J Med (2015) 5.66
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
Should small papillary thyroid cancer be observed? A population-based study. Cancer (2014) 2.21
Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer (2008) 2.09
Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg (2010) 1.70
A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid (2010) 1.68
DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J Clin Endocrinol Metab (2012) 1.67
Prospective randomized trial of ligasure versus harmonic hemostasis technique in thyroidectomy. Ann Surg Oncol (2010) 1.67
Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations. Arch Surg (2010) 1.66
Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab (2010) 1.57
Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer (2007) 1.52
MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer (2010) 1.51
Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid (2009) 1.41
Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease? Thyroid (2005) 1.40
Predictors of airway complications after thyroidectomy for substernal goiter. Arch Surg (2004) 1.37
Thyroid cancer gender disparity. Future Oncol (2010) 1.36
Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer (2011) 1.34
Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid (2010) 1.33
Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg (2010) 1.30
Parathyroid cancer. Semin Oncol (2010) 1.28
MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer (2011) 1.26
Accuracy of preoperative localization studies and intraoperative parathyroid hormone assay in patients with primary hyperparathyroidism and double adenoma. J Am Coll Surg (2003) 1.25
The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg (2008) 1.23
Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood (2011) 1.23
Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch Surg (2008) 1.18
Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg (2006) 1.16
Does familial non-medullary thyroid cancer adversely affect survival? World J Surg (2006) 1.15
Are additional localization studies and referral indicated for patients with primary hyperparathyroidism who have negative sestamibi scan results? Arch Surg (2010) 1.12
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 1.11
Thyroidectomy for Hashimoto's thyroiditis: complications and associated cancers. Thyroid (2008) 1.11
Is adrenal venous sampling necessary in all patients with hyperaldosteronism before adrenalectomy? J Vasc Interv Radiol (2008) 1.09
Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery (2004) 1.09
Malignant pheochromocytoma. Surg Oncol Clin N Am (2006) 1.06
Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Ann Surg Oncol (2011) 1.05
Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer (2009) 1.05
Recent developments in the clinical application of thyroid cancer biomarkers. Curr Opin Oncol (2008) 1.04
Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin. Thyroid (2013) 1.04
Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer (2010) 1.02
Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol (2015) 1.01
Laparoscopic adrenalectomy for malignancy. Surg Clin North Am (2004) 1.01
Palmitoylation controls the dynamics of budding-yeast heterochromatin via the telomere-binding protein Rif1. Proc Natl Acad Sci U S A (2011) 1.01
Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression. Endocrinology (2012) 1.00
Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection. World J Surg (2009) 0.99
Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid. World J Surg (2008) 0.99
Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J Proteome Res (2009) 0.99
Ectopic adrenocorticotropic hormone and corticotropin-releasing hormone co-secreting tumors in children and adolescents causing cushing syndrome: a diagnostic dilemma and how to solve it. J Clin Endocrinol Metab (2015) 0.98
Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation. J Surg Res (2009) 0.98
Reasons for conversion from laparoscopic to open or hand-assisted adrenalectomy: review of 261 laparoscopic adrenalectomies from 1993 to 2003. World J Surg (2004) 0.97
Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. J Clin Endocrinol Metab (2003) 0.97
Hook needle-guided excision of recurrent differentiated thyroid cancer in previously operated neck compartments: a safe technique for small, nonpalpable recurrent disease. J Clin Endocrinol Metab (2006) 0.96
What is the best criterion for the interpretation of adrenal vein sample results in patients with primary hyperaldosteronism? Ann Surg Oncol (2011) 0.95
Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. Thyroid (2012) 0.95
Patterns of antibiotic prophylaxis use for thyroidectomy and parathyroidectomy: results of an international survey of endocrine surgeons. J Am Coll Surg (2010) 0.95
MiR-886-3p regulates cell proliferation and migration, and is dysregulated in familial non-medullary thyroid cancer. PLoS One (2011) 0.94
Prognostic indications for Hürthle cell cancer. World J Surg (2004) 0.94
Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families. Surgery (2009) 0.93
Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. J Mol Med (Berl) (2014) 0.93
Multiple endocrine neoplasia type 2. Curr Treat Options Oncol (2004) 0.93
Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid. Am J Surg (2010) 0.92
Conversion of a replication origin to a silencer through a pathway shared by a Forkhead transcription factor and an S phase cyclin. Mol Biol Cell (2007) 0.91
The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas. Ann Surg (2014) 0.91
MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. Surgery (2013) 0.91
Use of the electrothermal vessel sealing system versus standard vessel ligation in thyroidectomy. Asian J Surg (2005) 0.90
An in vivo mouse model of metastatic human thyroid cancer. Thyroid (2014) 0.90
Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype. J Clin Endocrinol Metab (2013) 0.90
Summary statement: utility of molecular marker testing in thyroid cancer. Surgery (2010) 0.90
Selective use of steroid replacement after adrenalectomy: lessons from 331 consecutive cases. Arch Surg (2006) 0.89
A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery (2010) 0.89
Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery (2005) 0.89
TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer (2013) 0.89
Does the presence of additional thyroid nodules on ultrasound alter the risk of malignancy in patients with a follicular neoplasm of the thyroid? Surgery (2007) 0.88
Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors. World J Surg (2012) 0.88
Identification of differentially expressed microRNA in parathyroid tumors. Ann Surg Oncol (2010) 0.87
Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing. J Clin Endocrinol Metab (2011) 0.87
Association of type O blood with pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome. Ann Surg Oncol (2012) 0.86
Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms? Cancer (2008) 0.86
Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted? J Am Coll Surg (2013) 0.86
Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas. J Clin Endocrinol Metab (2013) 0.85
Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers. Surgery (2008) 0.85
Does routine consultation of thyroid fine-needle aspiration cytology change surgical management? J Am Coll Surg (2007) 0.85
Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. Surgery (2011) 0.84
Diagnosis of thyroid cancer: state of art. Expert Opin Med Diagn (2013) 0.84